9 October 2022 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Real world data (RWD) and real world evidence (RWE) is one of the most rapidly developing areas in the modern health care systems, which is caused by the development of technologies for both collecting and analyzing data, the emergence of new data sources and the formation of needs both by regulatory bodies, health technology assessment (HTA) agencies, and by the clinical and scientific communities. However, at the moment, there is no universal approach to RWD/E generation and application in the context of HTA. Over the past few years, the rate of including RWD/E in the HTA dossier has noticeably increased, but the nature of the existing guidelines and recommendations is rather fragmentary, which might create obstacles in the way of RWD/E study development and submission. The publication is aimed to describe and summarize the main and most rapidly developing spheres of RWD/E applications and analyze the possibilities of using RWD/E in various HTA areas in the world and in the Russian Federation considering the main trends in the further HTA development.
16 March 2023 in Medical Technologies. Assessment and Choice
Problems in terminology are typical for any developing area of knowledge including Real World Evidence. In particular, we deal with variability of terms (use of different terms and their meanings for the same definition) and questions of their motivation (use of various motivating factors leading to variability). Moreover, the terms «data», «study» and «Real World Evidence» in Russia are polysemantic and used in different meanings. Indeed, study is both data processing and source of routine practice data in the same time. Analysis of legislative documents of the Eurasian Economic Union (EAEU) shows that today they contain 2 phrases: routine clinical practice (term with certain definition) and real clinical practice (part of other terms without definition). We found similar problems in terminology at the global level analyzing www.clinicaltrials.gov. Understanding the development of terminology is significant regarding development and evaluation of classification of Real World Evidence studies. Real World Evidence was historically formed from pharmacoepidemiology and currently goes beyond this scientific discipline. The term «RWE studies» is complex and systemic. Its use in legislation may lead to conflicts between current legislation regulating a part of RWE study designs and new legislation that will regulate the RWE studies. That is, there may potentially be a situation of double regulation for some RWE designs. Therefore, the issues of classification of RWE studies and the use of this classification in legislation, especially in pharmacovigilance, registration and decision-making in healthcare, are extremely important. In this regard, there are new needs for further development, including the need for classification of RWE studies. Analyzing regulatory documents, guidelines and scientific publications, we formulated criteria to classify any RWE studies from traditional interventional to innovative hybrid researches. This approach makes it possible to indicate various study designs corresponding to RWE studies. Finally, structuring and systematization of knowledge in real world data and RWE studies are necessary for development of clear criteria in decision-making and application of RWE in healthcare.
24 April 2017 in Rheumatology Science and Practice
The investigators carried out an analysis of the efficacy and safety of secukinumab (SEC) in the randomized placebocontrolled trials (RPCTs) FUTURE 1 and FUTURE 2, as well as a subanalysis of the data obtained in the Russian population of patients with active psoriatic arthritis (PsA). The FUTURE 1 and FUTURE 2 trials enrolled a total of 1003 patients with active PsA. They received SEC (n = 703) or placebo (PL) (n = 300). The use of SEC 300 or 150 mg without previous intravenous (IV) loading dose or either 150 or 75 mg with the IV loading dose led to a significant improvement in patients with PsA. The positive changes in the main clinical manifestations of PsA at 24 weeks persisted until 52 weeks of therapy. SEC was effective in both the patients who had not previously received tumor necrosis factor-α inhibitors and those who had previously taken these drugs, and the result of therapy did not depend on concomitant methotrexate use.The incidence of cancer was low and comparable in the SEC and PL groups. Analysis of the combined data on the safety of the two RPCTs showed that the treatment duration-adjusted incidence of malignant neoplasms was 0.5 per 100 patient-years in the SEC groups and 0.9 in the PL groups. The safety profile of SEC in these RPCTs corresponds to that in the previous studies of the drug.The data from the pooled analysis of the Russian subpopulation of patients with PsA fully agree with the results obtained in the evaluation of all the patients included in FUTURE 1 and FUTURE 2 and confirm the most important role of IL-17А in the pathogenesis of PsA.
24 January 2023 in Real-World Data & Evidence
This article provides a brief overview of the key aspects of planning, conducting, and reporting NICE clinical practice data collection and analysis studies, as well as general information about the sources of real-world data (RWD) and their use in NICE management decision-making algorithms. The difficulties of finding and using RWD are described, as well as methods for overcoming them, brief NICE recommendations for assessing the suitability of data and an algorithm for conducting quantitative studies to collect evidence from RWD are given.
1 January 2021 in Farmaciya (Pharmacy)
SZSergey Kensarinovich Zyryanov
Sergey Kensarinovich Zyryanov
Определено место реальной клинической практики (РКП) в доказательной медицине и ее роль в современном здравоохранении на примере псориаза на основании работ, опубликованных в 2010-2020 гг. в базах данных MedLine, PubMed, CochraneLibrary. Рассмотрены преимущества и недостатки исследований РКП и рандомизированных клинических исследований (РКИ). Отмечено, что данные обоих типов исследований могут дополнять друг друга. В обозримом будущем РКИ останутся необходимыми для первоначального одобрения лекарств и методов лечения, которые должны быть первоначально продемонстрированы как эффективные в основной целевой группе и для основного показания в РКИ, прежде чем они могут быть введены в РКП. Исследования данных РКП позволят более эффективно идентифицировать нерешенные медицинские потребности и молекулярные мишени для дальнейшей разработки терапевтических подходов, регистрировать лекарственные препараты, а также расширять их спектр показания. По мере исправления недостатков в структуре исследований РКП важность этого метода будет расти в клинической, нормативной и экономической сферах...
1 December 2022 in Moscow University Biological Sciences Bulletin
Studying the functioning of various body systems in different vertebrates is one of the key tasks of comparative physiology. Teleost fishes are a large gro